Related Experiment Video
Updated: Aug 9, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Current perspectives in the recognition and management of psoriatic arthritis: implications for integrated patient
Abstract:
Psoriatic arthritis (PsA), a chronic and debilitating spondyloarthropathy, is believed to affect as many as 30% of those with psoriasis. The use of tumor necrosis factor (TNF) inhibitors shows promise in the treatment of PsA and psoriasis. Etanercept, the first TNF inhibitor to be approved for use in PsA, inhibits the proinflammatory cytokine TNF in both conditions, making it possible for the clinician to prescribe a single agent to manage both the joint manifestations of PsA and the cutaneous manifestations of psoriasis. Etanercept has been shown to be well tolerated, even for long-term use, and is potentially superior to disease-modifying antirheumatic drugs.
Related Concept Videos
Patient-centered Care
Methods of Documentation VI: Case Management Model
For example, a patient with a chronic illness...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Chronic Pancreatitis II: Collaborative Care
Assessment:
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease IV: Nursing Management

